Effects of Ticagrelor on Left Ventricular Remodeling and Cardiac Function After AMI in Mice
Objective To investigate the effects of ticagrelor on left ventricular remodeling and cardiac function after acute myocardial infarction(AMI)in mice.Methods Eight-week-old male C57BL/6 mice were randomly divided into five groups:Sham group,AMI group,ticagrelor treatment group,ticagrelor pretreatment group,and ticagrelor pretreatment+treatment group.All groups,except for the Sham group,underwent left anterior descending coronary artery ligation to establish an AMI model.The ticagrelor treatment group received medication post-modeling,the pretreatment group pre-modeling,and the pretreatment+treatment group both pre-and post-modeling.Groups were compared for left ventricular function[left ventricular fractional shortening(LVFS),left ventricular end-diastolic diameter(LVEDD),and left ventricular end-systolic diameter(LVESD)],inflammatory markers[IL-6 and TNF-α],cardiac index,and mRNA expression levels of serum atrial natriuretic peptide(ANP)and brain natriuretic peptide(BNP).Results The left ventricular fractional shortening(LVFS)of the Sham group,the Ticagrelor treatment group,and the Ticagrelor pretreatment+treatment group[(42.12±5.20)%,(39.63±5.75)%,and(41.72±6.31)%]was higher than that of the AMI group[(33.98±5.21)%],with a statistically significant difference(P<0.05).In contrast,the left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)were lower in the Sham group,the Ticagrelor treatment group,and the Ticagrelor pretreatment+treatment group[(3.59±0.61)mm,(4.03±0.65)mm,and(3.96±0.73)mm compared to(4.79±0.74)mm;(2.13±0.40)mm,(2.39±0.56)mm,and(2.29±0.48)mm compared to(2.93±0.54)mm],with statistically significant differences(P<0.05).The levels of inflammatory factors IL-6 and TNF-α in the Sham group,the Ticagrelor treatment group,and the Ticagrelor pretreatment+treatment group were lower than those in the AMI group[(110.50±25.34)pg/mL,(202.28±55.24)pg/mL,and(189.49±43.31)pg/m L vs.(359.48±80.10)pg/mL;(24.59±6.95)pg/mL,(51.28±14.03)pg/mL,and(47.49±11.16)pg/mL vs.(81.92±15.55)pg/mL],with statistically significant differences(P<0.001).The cardiac index of the Sham group,the Ticagrelor treatment group,and the Ticagrelor pretreatment+treatment group were(4.90±0.84),(5.44±0.90),and(5.31±0.84),respectively,which were lower than that of the AMI group(6.39±1.29),with a statistically significant difference(P<0.05).The cardiac index of the Ticagrelor pretreatment group was(6.21±1.04)points,with no statistically significant difference compared to the AMI group(P>0.05).The mRNA expression levels of ANP and BNP in the Sham group,the Ticagrelor treatment group,and the Ticagrelor pretreatment+treatment group were lower than those in the AMI group[(1.22±0.34),(1.83±0.54),and(1.80±0.57)compared to(2.66±0.69);(1.08±0.24),(1.48±0.56),and(1.38±0.49)compared to(2.45±0.75)],with statistically significant differences(P<0.001).Conclusion Ticagrelor can improve left ventricular function in mice after AMI,enhance cardiac contractile function,reduce effectively ventricular dilation,and alleviate myocarditis and cardiac load.
NETL
NSTL
万方数据
